2024
Correlation between changes in apathy and cognition in Alzheimer’s disease associated apathy: Analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2)
Sankhe K, Tumati S, Perin J, Rivet L, Vieira D, Rosenberg P, Herrmann N, Shade D, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Mintzer J, Lanctôt K. Correlation between changes in apathy and cognition in Alzheimer’s disease associated apathy: Analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2). International Psychogeriatrics 2024, 37: 100012. PMID: 40086910, DOI: 10.1016/j.inpsyc.2024.100012.Peer-Reviewed Original ResearchBoston Naming TestMini-Mental State ExamCategory fluencyMild-to-moderate AD patientsClinically significant apathyCognitive change scoresModerate AD patientsHopkins Verbal LearningVerbal learningDigit spanNaming TestVerbal fluencySignificant apathyTrail MakingCognitive changesMeasure apathyMethylphenidateCognitionCognitive scoresState ExamMini-MentalChange scoresApathyAD patientsTrial 2A preliminary examination of the TOMM2 in a sample of Spanish speakers in the United States
Usuga D, Ayearst L, Rivera D, Krch D, Perrin P, Carrión C, Valdés G, Loro D, Rodriguez M, Munoz G, Drago C, García P, Rivera P, Arango-Lasprilla J. A preliminary examination of the TOMM2 in a sample of Spanish speakers in the United States. NeuroRehabilitation An International Interdisciplinary Journal 2024, 55: 235-242. PMID: 39240592, DOI: 10.3233/nre-240085.Peer-Reviewed Original ResearchConceptsNormative dataPerformance validity measuresSpanish speakersItem-level analysesCognitively healthy adultsRecognition trialsNormative samplePsychiatric disordersTOMMCutoff scoreSpanish versionHispanic individualsDescriptive normsU.S. METHODSValidity measuresCultural appropriatenessHealthy adultsDescriptive analysisTrial 1ScoresItemsSpeakersTrial 2United StatesCognition
2023
Blood‐based biomarkers for predicting treatment response in the Apathy in Dementia Methylphenidate Trial 2 randomized clinical trial
Tumati S, Vieira D, Bawa K, Andreazza A, Mintzer J, Scherer R, Rosenberg P, van Dyck C, Padala P, Brawman‐Mintzer O, Porsteinsson A, Lerner A, Craft S, Levey A, Burke W, Perin J, Shade D, Herrmann N, Lanctôt K. Blood‐based biomarkers for predicting treatment response in the Apathy in Dementia Methylphenidate Trial 2 randomized clinical trial. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.079161.Peer-Reviewed Original ResearchCost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2)
Lanctôt K, Chen C, Mah E, Kiss A, Li A, Shade D, Scherer R, Vieira D, Coulibaly H, Rosenberg P, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Burke W, Mintzer J, Herrmann N. Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2). International Psychogeriatrics 2023, 35: 664-672. PMID: 37066690, PMCID: PMC10579450, DOI: 10.1017/s1041610223000327.Peer-Reviewed Original ResearchConceptsCost-consequence analysisTreatment of apathyFive-level questionnaireTrial 2Quality of lifeBinary logistic regressionPlacebo groupPlacebo treatmentMethylphenidate treatmentSignificant apathyHealth utilityResource utilization costsAlzheimer's diseaseLogistic regressionMethylphenidateTime interactionLevel questionnaireHealthcare systemCost predictorsMeasures analysisPatientsTreatmentDiseaseMonthsUtilization costs
2022
012 Two-Year Administration Data of an Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men
Swerdloff R, Honig S, Wang C, Gittelman M, Seo B, Rohowsky N, Dudley R. 012 Two-Year Administration Data of an Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men. The Journal Of Sexual Medicine 2022, 19: s128-s128. DOI: 10.1016/j.jsxm.2022.03.548.Peer-Reviewed Original ResearchTestosterone replacement therapyHypogonadal menOral TUEugonadal rangeSystolic BPSafety profileTrial 2T concentrationsDose-titration trialInjection site painMo of therapyDays of therapyIPSS total scoreLong-term efficacyTrial 1Two-year followMean T concentrationsLong-term extensionPreferred administration routeMen ages 18CV endpointsLFT elevationsALT levelsSite painAE reporting3 Two-Year Administration Data of an Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men
Swerdloff R, Honig S, Wang C, Gittelman M, Seo B, Rohowsky N, Dudley R. 3 Two-Year Administration Data of an Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men. The Journal Of Sexual Medicine 2022, 19: s2-s2. DOI: 10.1016/j.jsxm.2022.01.014.Peer-Reviewed Original ResearchTestosterone replacement therapyHypogonadal menOral TUEugonadal rangeSystolic BPSafety profileTrial 2T concentrationsDose-titration trialInjection site painMo of therapyDays of therapyIPSS total scoreLong-term efficacyTrial 1Two-year followMean T concentrationsLong-term extensionPreferred administration routeMen ages 18CV endpointsLFT elevationsALT levelsSite painAE reporting
2021
The protocol of the Application of Economics & Social psychology to improve Opioid Prescribing Safety trial 2 (AESOPS-2): Availability of opioid harm
Kelley M, Persell S, Linder J, Friedberg M, Meeker D, Fox C, Goldstein N, Knight T, Zein D, Sullivan M, Doctor J. The protocol of the Application of Economics & Social psychology to improve Opioid Prescribing Safety trial 2 (AESOPS-2): Availability of opioid harm. Contemporary Clinical Trials 2021, 112: 106650. PMID: 34896295, PMCID: PMC8869359, DOI: 10.1016/j.cct.2021.106650.Peer-Reviewed Original ResearchConceptsProportion of patientsOpioid-related overdosesOpioid prescribingOpioid-related harmsOpioid use disorderTrial 2Mixed effects regression modelsHarmful patient outcomesDaily MMEMorphine equivalentsPatient overdoseUsual careOpioid usePrimary outcomePrescriber awarenessOpioid harmsPrescribing SafetyPrevention recommendationsIntervention groupPatient outcomesOpioid overdosesUse disordersTreat differencesDisease controlAdditional outcomes
2017
Customized Recommendations and Reminder Text Messages for Automated, Computer-Based Treatment During Methadone
Moore BA, Buono FD, Printz DMB, Lloyd DP, Fiellin DA, Cutter CJ, Schottenfeld RS, Barry DT. Customized Recommendations and Reminder Text Messages for Automated, Computer-Based Treatment During Methadone. Experimental And Clinical Psychopharmacology 2017, 25: 485-495. PMID: 29251978, PMCID: PMC5737744, DOI: 10.1037/pha0000149.Peer-Reviewed Original ResearchConceptsCognitive behavioral therapyPatient engagementReminder messagesPreliminary efficacy findingsMethadone-maintained patientsSubstance use disordersIllicit drug useRandomized trialsEfficacy findingsMethadone maintenanceUse disordersPatient useDrug useSystem functionBehavioral therapyComputer-based interventionsPatientsShort latencyTotal call timeTrial 2Trial 1Line callsSelf-management systemCall timeTotal contact time[O1–01–06]: MEASURING APATHY IN ALZHEIMER'S DISEASE IN THE APATHY IN DEMENTIA METHYLPHENIDATE TRIAL 2 (ADMET 2): A COMPARISON OF INSTRUMENTS
Lanctot K, Scherer R, Li A, Rosenberg P, Herrmann N, Lerner A, Padala P, Brawman‐Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Burke W, Mintzer J. [O1–01–06]: MEASURING APATHY IN ALZHEIMER'S DISEASE IN THE APATHY IN DEMENTIA METHYLPHENIDATE TRIAL 2 (ADMET 2): A COMPARISON OF INSTRUMENTS. Alzheimer's & Dementia 2017, 13: p184-p184. DOI: 10.1016/j.jalz.2017.07.038.Peer-Reviewed Original Research
2008
Effects of prenatal cocaine exposure on infant reactivity and regulation
Eiden RD, McAuliffe S, Kachadourian L, Coles C, Colder C, Schuetze P. Effects of prenatal cocaine exposure on infant reactivity and regulation. Neurotoxicology And Teratology 2008, 31: 60-68. PMID: 18822371, PMCID: PMC2631277, DOI: 10.1016/j.ntt.2008.08.005.Peer-Reviewed Original ResearchConceptsPrenatal cocaine exposureCocaine exposureBirth weightInfant birth weightLow birth weightControl group infantsHigh birth weightInfant reactivityArm restraint procedureMother-infant dyadsGroup infantsRisk factorsOngoing longitudinal studyInfant ageInfant regulationInfantsTrial 2Trial 1Longitudinal studyCocaineRestraint procedureExposureLevel of stressAnger/frustrationWeightTegaserod Treatment for Dysmotility-Like Functional Dyspepsia: Results of Two Randomized, Controlled Trials
Vakil N, Laine L, Talley NJ, Zakko SF, Tack J, Chey WD, Kralstein J, Earnest DL, Ligozio G, Cohard-Radice M. Tegaserod Treatment for Dysmotility-Like Functional Dyspepsia: Results of Two Randomized, Controlled Trials. The American Journal Of Gastroenterology 2008, 103: ajg2008383. PMID: 18616658, DOI: 10.1111/j.1572-0241.2008.01953.x.Peer-Reviewed Original ResearchConceptsDysmotility-like functional dyspepsiaFunctional dyspepsiaSatisfactory symptom reliefTegaserod treatmentSymptom reliefDaily severity scoresPlacebo-controlled trialSevere baseline symptomsHelicobacter pylori statusTrial 2Trial 1Percentage of daysEarly satietyIdentical multicenterPostprandial fullnessStudy discontinuationAbdominal discomfortControlled TrialsMedication usePylori statusSeverity scoreReceptor agonistBaseline symptomsTegaserodClinical implications
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply